Coronavirus COVID vaccine India Oxford UK WHO Moderna Russia US News Update: We are tracking the latest status from Oxford-AstraZeneca, Moderna, Russia, US, India.
Coronavirus COVID vaccine India Oxford UK WHO Moderna Russia US News Update: The Phase I human trial of India’s first indigenous potential Coronavirus vaccine candidate COVAXIN has started. A man in his 30s has been vaccinated. The first volunteer, a resident of Delhi, was screened two days ago and all his health parameters were found to be within the normal range. He also does not have any co-morbid conditions. The first dose of 0.5 ml intramuscular injection was given to him around 1.30 pm. No immediate side-effects have been observed so far. He was under observation for two hours and will be monitored for the next seven days, AIIMS official was quoted as saying by PTI. Few more participants would be given the vaccine on Saturday after their screening reports come.
More than 25 potential Coronavirus COVID19 vaccines have managed to enter the Human Trials phase. However, the potential Coronavirus Covid19 vaccines, which are being developed by UK’s Oxford-AstraZeneca, US-based Moderna, India’s COVAXIN, Russia, China companies and Pfizer-BioNTech, have raised hopes. While people around are eagerly waiting for Coronavirus vaccine, experts including those associated with the World Health Organisation (WHO) have claimed that a COVID19 vaccine can arrive at the market by the first quarter of 2021.
Oxford-AstraZeneca’s potential COVID-19 vaccine has shown positive results so far during its Phase 1 and Phase 2 human trials. Adar Poonawalla-headed Serum Institute of India has tied up with the Oxford-AstraZeneca vaccine to produce the vaccine in India when it is ready. The Oxford-AstraZeneca’s COVID-19 vaccine in India will be called ‘Covishield’. The likely cost of the coronavirus vaccine in India would be Rs 1000 per dose. Meanwhile, in the US, the Donald Trump administration has announced a USD 1.95 billion deal with Pfizer Inc. and BioNTech to purchase the potential COVID19 vaccine once it is ready. This deal means the price of the Coronavirus COVID19 vaccine would be USD 20 per dose.
Coronavirus vaccine Oxford, Astra Zeneca
Oxford-AstraZeneca’s potential coronavirus vaccine candidate has produced a “strong immune response”. The large scale clinical trials for the third stage is taking place in Brazil and South Africa. Oxford scientists are confident of discovering a “safe, effective, and accessible vaccine against coronavirus.” A few days back Oxford researcher Sarah Gilbert said that end of 2020 rollout of vaccine is a “possibility” but not “certainty”.
Coronavirus vaccine India, COVAXIN
India’s first indigenous COVID-19 Vaccine COVAXIN is being developed by Bharat Biotech, Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). Phase I and II Human Clinical Trials of the vaccine are going on and results are expected in two to three months.
Coronavirus vaccine Moderna, US, Pfizer, BioNTech
The Donald Trump administration in the US has said that the American governemnt will pay USD 1.95 billion to buy 100 million doses of Pfizer’s and German biotech firm BioNTech’s potential COVID-19 vaccine candidate. Pfizer-BioNTech is expected to start Phase III trials this month. Meanwhile, US-based Moderna is developing mRNA-1273 vaccine against coronavirus. Moderna has said that Time is of the essence to provide a vaccine against this pandemic virus. It will start late-stage human trials by July end.
Russia has already announced that it has developed “world’s first coronavirus vaccine” and claimed that the vaccine has been tested and it was found to be “safe”. Now, Prime Minister of Mikhail Mishustin has claimed that his country would produce a “reliable vaccine” against coronavirus by “the fall”. Mishustin has also revealed that 17 scientific organizations are working on more than 26 types of potential coronavirus vaccines. Notably, Fall 2020 will commence on September 22.